Page last updated: 2024-09-05
opc 4392 and bifeprunox
opc 4392 has been researched along with bifeprunox in 1 studies
Compound Research Comparison
| Studies (opc 4392) | Trials (opc 4392) | Recent Studies (post-2010) (opc 4392) | Studies (bifeprunox) | Trials (bifeprunox) | Recent Studies (post-2010) (bifeprunox) |
|---|---|---|---|---|---|
| 16 | 1 | 0 | 30 | 1 | 12 |
Protein Interaction Comparison
| Protein | Taxonomy | opc 4392 (IC50) | bifeprunox (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.0029 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
Other Studies
1 other study(ies) available for opc 4392 and bifeprunox
| Article | Year |
|---|---|
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |